Ashler et Manson (XPAR:MLAEM) Research & Development: €0.00 Mil (TTM As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:MLAEM Ashler et Manson SA XPAR:MLAEM
80 GF Score
Price €2.60
GF Value €2.62
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Ashler et Manson Research & Development?

Ashler et Manson XPAR:MLAEM -14.47% 80 Research & Development is €0.00 Mil as of Dec. 2024. GuruFocus rates XPAR:MLAEM with a GF Score™ of 80/100 and a GF Value™ of €2.62 (Fairly Valued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Ashler et Manson's Research & Development for the six months ended in Dec. 2024 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Ashler et Manson  (XPAR:MLAEM) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Ashler et Manson Research & Development Related Terms

Ashler et Manson Research & Development Historical Data

* Premium members only.

The historical data trend for Ashler et Manson's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ashler et Manson Research & Development Chart

Ashler et Manson Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ashler et Manson Semi-Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XPAR:MLAEM
80GF Score
Ashler et Manson SA XPAR:MLAEM
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ashler et Manson Research & Development Calculation

This is the expense the company spent on research and development.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
Ashler et Manson (XPAR:MLAEM) has a Research & Development of €0.00 Mil as of Dec. 2024. Research and development expense is the total cost for research and development activities. View historical data on Ashler et Manson and its competitors.
Is Ashler et Manson's Research & Development too high?
Ashler et Manson's current Research & Development is €0.00 Mil. Overall, Ashler et Manson has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ashler et Manson's Research & Development compare to MRSH and AON?
Ashler et Manson's Research & Development of €0.00 Mil can be compared against companies in the Insurance industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Insurance company?
A good Research & Development depends on the Insurance industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Ashler et Manson and its competitors. Ashler et Manson's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ashler et Manson stock overvalued right now?
Based on GuruFocus' analysis, Ashler et Manson (XPAR:MLAEM) is currently considered Fairly Valued. The stock's GF Value™ is €2.62, compared to a current price of €2.60 — trading 0.8% below its estimated fair value. The current Research & Development is €0.00 Mil. Ashler et Manson's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Ashler et Manson (XPAR:MLAEM), the current Research & Development is €0.00 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ashler et Manson (XPAR:MLAEM) Overvalued in 2026?

Based on GuruFocus' analysis, Ashler et Manson stock appears to be undervalued. The current stock price of €2.60 is trading 0.8% below its estimated GF Value™ of €2.62. GuruFocus considers Ashler et Manson to be Fairly Valued.

Key valuation signals for XPAR:MLAEM:

  • Research & Development: €0.00 Mil
  • GF Value™: €2.62 vs. price of €2.60 (0.8% below fair value)
  • GF Score™: 80/100 with 2 warning signs

No single metric tells the full story. See the XPAR:MLAEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ashler et Manson Business Description

Address 2 Allees d'Orleans, Bordeaux, FRA, 33000
Ashler et Manson SA is a France-based brokerage group in real estate credit and loan insurance sector.
80GF Score

Get the complete analysis for XPAR:MLAEM

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.60
Price
€2.62
GF Value